Scinai Immunotherapeutics Ltd. (SCNI)Healthcare | Biotechnology | Jerusalem, Israel | NasdaqCM
2.51 USD
-0.17
(-6.343%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 2.50 -0.01 (-0.010%) ⇩ (Aug. 28, 2026, 7:56 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 5:04 a.m. EDT
The immediate outlook is severely clouded by a massive 13% downside bias in the short-term forecast, which aligns with the stock testing critical support levels near $0.27 and dropping nearly 4% recently. While the company just secured $2.61 million in private financing to fund drug manufacturing, this cash infusion is insufficient to offset the structural reality that the business has suffered five consecutive years of declining revenue, with the last five annual periods showing negative growth. The balance sheet is fragile, carrying more debt than cash on hand, and the company is burning through operating cash flow rapidly. With no dividend history to speak of and a market capitalization under $2 million, there is no safety net for investors. The recent price action shows some volatility, but the trend remains firmly downward, making this a high-risk speculative vehicle rather than a viable investment. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.138355 |
| AutoARIMA | 0.238935 |
| AutoETS | 0.239537 |
| MSTL | 0.260244 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 30% |
| H-stat | 4.42 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.031 |
| Excess Kurtosis | 0.57 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 30.515 |
| Revenue per Share | 2.799 |
| Market Cap | 1,700,728 |
| Trailing P/E | 0.09 |
| Beta | 2.09 |
| Profit Margins | -174.78% |
| Previous Name | BiondVax Pharmaceuticals Ltd. |
| Website | https://www.scinai.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.82597405 |
| Address1 | Jerusalem BioPark |
| Address2 | 2nd Floor Hadassah Ein Kerem Campus |
| All Time High | 62,000.0 |
| All Time Low | 2.15 |
| Ask | 3.03 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 129,060 |
| Average Daily Volume3 Month | 66,806 |
| Average Volume | 66,806 |
| Average Volume10Days | 129,060 |
| Beta | 2.09 |
| Bid | 2.15 |
| Bid Size | 1 |
| Book Value | 1.735 |
| City | Jerusalem |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Israel |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.51 |
| Current Ratio | 1.563 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 2.98 |
| Day Low | 2.4 |
| Debt To Equity | 30.515 |
| Display Name | Scinai Immunotherapeutics |
| Ebitda | -6,636,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.203 |
| Enterprise To Revenue | 5.369 |
| Enterprise Value | 7,983,755 |
| Eps Trailing Twelve Months | 28.07 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 972 8 930 2531 |
| Fifty Day Average | 2.637 |
| Fifty Day Average Change | -0.1270001 |
| Fifty Day Average Change Percent | -0.04816082 |
| Fifty Two Week Change Percent | -82.597404 |
| Fifty Two Week High | 16.8 |
| Fifty Two Week High Change | -14.289999 |
| Fifty Two Week High Change Percent | -0.85059524 |
| Fifty Two Week Low | 2.15 |
| Fifty Two Week Low Change | 0.3599999 |
| Fifty Two Week Low Change Percent | 0.1674418 |
| Fifty Two Week Range | 2.15 - 16.8 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,431,351,000,000 |
| Float Shares | 488,725 |
| Free Cashflow | -3,657,250 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 45 |
| Fullday Change | -0.17 |
| Fullday Change Percent | -6.34329 |
| Fullday Price | 2.5 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | -2.5232 |
| Gross Profits | -3,752,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.14159 |
| Held Percent Institutions | 0.04295 |
| Implied Shares Outstanding | 677,581 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,787,270,400 |
| Last Split Factor | 1:10 |
| Long Business Summary | Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis. The company also offers contract development and manufacturing organization services, such as analytical method development, process development, and cGMP manufacturing of clinical-stage materials to early-stage biotechnology companies. It has collaboration partnerships with Max Planck Society and University Medical Center Gottingen for the development of NanoAb candidates; and Recipharm Israel Ltd for the development of biologics and small-molecule programs. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is based in Jerusalem, Israel. |
| Long Name | Scinai Immunotherapeutics Ltd. |
| Market | us_market |
| Market Cap | 1,700,728 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_9300995 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-08-28 |
| Net Income To Common | -2,599,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,822,691 |
| Open | 2.7 |
| Operating Cashflow | -7,376,000 |
| Operating Margins | -4.6652203 |
| Payout Ratio | 0.0 |
| Phone | 972 8 930 2529 |
| Post Market Change | -0.00999999 |
| Post Market Change Percent | -0.398406 |
| Post Market Price | 2.5 |
| Post Market Time | 1,787,961,406 |
| Prev Name | BiondVax Pharmaceuticals Ltd. |
| Previous Close | 2.68 |
| Price Hint | 4 |
| Price To Book | 1.4466859 |
| Price To Sales Trailing12 Months | 1.143731 |
| Profit Margins | -1.74781 |
| Quick Ratio | 1.222 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.17 |
| Regular Market Change Percent | -6.34329 |
| Regular Market Day High | 2.98 |
| Regular Market Day Low | 2.4 |
| Regular Market Day Range | 2.4 - 2.98 |
| Regular Market Open | 2.7 |
| Regular Market Previous Close | 2.68 |
| Regular Market Price | 2.51 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 36,895 |
| Return On Assets | -0.36154 |
| Return On Equity | -0.26534 |
| Revenue Growth | 1.46 |
| Revenue Per Share | 2.799 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 677,581 |
| Shares Percent Shares Out | 0.0136 |
| Shares Short | 7,025 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 45,518 |
| Short Name | Scinai Immunotherapeutics Ltd. |
| Short Percent Of Float | 0.0143 |
| Short Ratio | 0.1 |
| Source Interval | 15 |
| Symbol | SCNI |
| Total Cash | 2,654,000 |
| Total Cash Per Share | 4.656 |
| Total Debt | 3,580,000 |
| Total Revenue | 1,487,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 28.07 |
| Trailing P E | 0.08941931 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 6.2357 |
| Two Hundred Day Average Change | -3.7257001 |
| Two Hundred Day Average Change Percent | -0.59747905 |
| Type Disp | Equity |
| Volume | 36,895 |
| Website | https://www.scinai.com |